Table 1.
Study cohort clinical characteristics by total 68Ga-DOTATATE avid tumor volume quartiles
| Q1 n=46 |
Q2 n=46 |
Q3 n=46 |
Q4 n=46 |
P value | |
|---|---|---|---|---|---|
| Age (years) | 52·7±16·1 | 54·7±14·6 | 56·9±13·3 | 56·8±12·4 | NS |
| Female n (%) | 23 (50·0%) | 29 (63·0%) | 24(52·2%) | 19 (41·3%) | NS |
| Disease progression during follow-up n(%) | 3 (8·8%) | 18 (53·9%) | 18 (47·4%) | 18 (54·5%) | 0·001 |
| Died of disease during Follow-up n (%) | 0 | 1 (2·2%) | 2 (4·3%) | 8 (17·4%) | 0·002 |
| Time since diagnosis (months) | 3·2±3·7 | 6.2±6·4 | 7·9±7·7 | 3·8±4·5 | 0.001 |
| F/u duration (months) | 18·4±8·4 | 21·4±8·0 | 19·7±7·8 | 17·0±7·4 | 0·05 |
| NET subtype | NS | ||||
| PNET | 24 (52·2%) | 27 (58·7%) | 23 (50·0%) | 25 (54·3%) | |
| SINET | 11 (23·9%) | 12 (26·1%) | 17 (37·0%) | 17 (37·0%) | |
| Unknown primary | 4 (8·7%) | 5 (10·9%) | 1 (2·2%) | 3 (6·5%) | |
| Other | 7 (15·2%) | 2 (4·3%) | 5 (10·9%) | 1 (2·2%) | |
| SUVmax | 32·7±22·3 | 70·2±52·4 | 83·4±46·9 | 90·3±55·5 | <0·001 |
| 68Ga-DOTATATE TV (mL) | 1·2±0·8 | 6·4±2·0 | 24·1±10·6 | 245·1±227·1 | <0·001 |
| Treatment after inclusion | |||||
| Medical n (%) | 14 (31·1%) | 23 (50·0%) | 18 (39·1%) | 31 (68·9%) | 0·002 |
| Surgical n (%) | 11 (24·4%) | 10 (21·7%) | 12 (26·1%) | 9 (20·0) | NS |
| PRRT n(%) | 0 | 3 (6·5%) | 2 (4·3%) | 5 (11·1%) | NS |
| LDT n(%) | 0 | 2 (4·3%) | 0 | 2 (4·3%) | NS |
| WHO 2010 grading | NS | ||||
| G1 | 11 (64·7%) | 6 (40·0%) | 11 (45·8%) | 11 (44·0%) | |
| G2 | 5 (29·4%) | 9 (60·0%) | 13 (54·2%) | 11 (44·0%) | |
| G3 | 1 (5·9%) | 0 | 0 | 3 (12·0%) | |
| Disease stage n (%)* | <0·001 | ||||
| I | 21 (45·7%) | 10 (21·7%) | 3 (6·5%) | 0 | |
| II | 7 (15·2%) | 1 (2·2%) | 3 (6·5%) | 1 (2·2%) | |
| III | 10 (21·7%) | 10 (21·7%) | 9 (19·6%) | 5 (10·9%) | |
| IV | 8 (17·4%) | 25 (54·3%) | 31 (67·4%) | 40 (87·0%) | |
| Plasma CGA (ng/mL) | 213±374 | 627±1242 | 693±1353 | 7220±37446 | NS |
| Urinary 5HIAA (mg/24h) | 4·8±1·8 | 5·7±3·7 | 7·6±5·3 | 30·6±47·0 | <0·001 |
| Plasma NSE (ng/mL) | 9·4±3·8 | 28·6±59·4 | 10·8±7·4 | 14·3±10·9 | NS |
| Plasma gastrin (pg/mL) | 81±126 | 125±241 | 461±1398 | 159±454 | NS |
| Plasma glucagon (pg/mL) | 37·9±20·4 | 42·2±36·9 | 40·4±33·3 | 55·8±73·1 | NS |
| Plasma PP (pg/mL) | 147±84 | 240±293 | 198±248 | 427±995 | NS |
| Plasma VIP (pg/mL) | 33·3±13·3 | 37·9±15·9 | 36·8±12·8 | 47·7±53·0 | NS |
NS, non-significant; f/u, follow-up; NET, neuroendocrine tumor; PNET, pancreatic neuroendocrine tumor; SINET, small intestine neuroendocrine tumor; SUVmax, maximal standardized uptake values in 68Ga-DOTATATE PET/CT; 68Ga-DOTATATE TV, total 68Ga-DOTATATE-avid tumor volume; SSA, somatostatin analogs; LDT, liver-directed therapy; WHO, World Health Organization; CGA, chromogranin A; 5HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; PP, pancreatic polypeptide; VIP, vasoactive intestinal peptide
Continuous variables are presented as mean±standard deviation
Tumor staging was determined according to the American Joint Committee on Cancer, 8th edition.